AB Science strengthens its cash flow with a capital increase

AB Science announced the completion of a €1.8 million capital increase. This transaction was subscribed by a limited number of investors and allows the company to secure its financing needs for at least the next year. The company, listed on Euronext Paris, thus highlights its ability to strengthen its financial position as part of its future projects.

Specializing in the development of protein kinase inhibitors, AB Science continues to focus on diseases with high unmet medical need. The funding supports the development of products such as masitinib in oncology and inflammatory diseases.